10058-F4: Unraveling c-Myc-Max Inhibition in Stem Cell Telomerase Control

Introduction: Moving Beyond Cancer Models—A Stem Cell Perspective

The c-Myc-Max axis is a central node in transcriptional regulation, governing cell proliferation, differentiation, and survival across multiple biological systems. While targeting this dimerization has revolutionized cancer research, particularly in apoptosis and leukemia models, recent evidence spotlights its pivotal role in telomerase (TERT) control within human pluripotent stem cells (reference paper). This article delivers a comprehensive analysis of 10058-F4 C-Myc-Max dimerization inhibitor (SKU: A1169), emphasizing its emerging value for stem cell and telomere biology—an area underexplored in prior reviews, which focus largely on oncogenic pathways and apoptosis assay optimization.

Mechanism of Action: 10058-F4 as a Precision Tool for c-Myc-Max Disruption

10058-F4 is a small-molecule inhibitor that selectively disrupts the heterodimerization of c-Myc and Max, a prerequisite for c-Myc's transcriptional activity (product_spec). By blocking this interaction, 10058-F4 impedes c-Myc's ability to bind DNA, resulting in downregulation of its downstream targets, including the critical mitochondrial coactivator PGC-1β. This cascade leads to cell cycle arrest and triggers apoptosis predominantly via the mitochondrial pathway, characterized by a decrease in Bcl-2, an increase in Bax, and the release of cytochrome C.

Crucially, in acute myeloid leukemia (AML) cell lines (HL-60, U937, NB-4), 10058-F4 not only induces myeloid differentiation but also reduces both c-Myc mRNA and protein levels, reinforcing its utility as a c-Myc transcription factor inhibition tool (source: product_spec).

Reference Insight Extraction: The Breakthrough in TERT Regulation

While previous literature has centered on oncogenic and apoptosis pathways, the recent study by Kotian et al. (reference paper) reveals a transformative role for c-Myc-Max dimerization in regulating telomerase (TERT) transcription in human pluripotent stem cells. The key innovation is the demonstration that pharmacological inhibition of c-Myc-Max (using a dimerization inhibitor) rapidly increases repressive histone marks (H3K27me3) at the TERT promoter, leading to suppressed TERT expression. This finding provides a direct mechanistic link between c-Myc-Max activity and telomere maintenance, a critical determinant of stem cell longevity and proliferative potential.

For researchers, this means that 10058-F4 is not just a cancer biology tool—it is now a precise molecular switch for studying epigenetic regulation of telomerase in stem cells, enabling interrogation of developmental aging and disease models that extend well beyond traditional oncology applications.

Protocol Parameters

• apoptosis assay | 10–50 μM | leukemia & solid tumor cell lines | Empirically shown to induce c-Myc-dependent mitochondrial apoptosis | product_spec
• TERT repression in hESC | 10 μM | human pluripotent stem cells | Sufficient to induce H3K27me3 at TERT promoter and reduce TERT mRNA within hours | reference paper
• In vivo tumor suppression | 20–30 mg/kg, i.v., once daily, 2 weeks | SCID mice with prostate cancer xenografts | Achieved significant tumor control in DU145 and PC-3 models | product_spec
• Stock solution preparation | ≥12.5 mg/mL in DMSO; warm to 37°C or sonicate | General use | Ensures full solubilization for reproducible dosing | workflow_recommendation
• Storage | -20°C, solid or solution (short term only) | All applications | Maintains compound stability; avoid long-term solution storage | workflow_recommendation

Comparative Analysis: Differentiating from Prior Work

Existing articles, such as 'Disrupting c-Myc-Max Dimerization: Next-Generation Strategies', spotlight 10058-F4's translational promise in oncology, integrating telomerase regulation primarily as an adjunct to cancer pathway analysis. In contrast, our focus here is on direct modulation of TERT in stem cell systems, unpacking the broader regulatory circuit that governs cellular immortality and developmental biology.

Similarly, '10058-F4 (SKU A1169): Optimizing c-Myc-Max Inhibition for Apoptosis and Proliferation Assays' delivers valuable troubleshooting for cell death and proliferation experiments. However, it does not address the epigenetic or telomere-centric impacts that are illuminated by recent stem cell studies. Our analysis builds upon these foundations by providing actionable guidance for researchers seeking to dissect telomerase and chromatin regulation, extending the utility of 10058-F4 into new biological contexts.

Advanced Applications: Telomerase Regulation, Stem Cell Aging, and Beyond

The intersection of c-Myc-Max inhibition and TERT repression opens new research frontiers:

• Modeling Telomere Biology Disorders: By modulating TERT expression epigenetically, 10058-F4 enables precise modeling of diseases such as dyskeratosis congenita or idiopathic pulmonary fibrosis, where telomere maintenance is pathologically disrupted (reference paper).
• Stem Cell Proliferation and Aging: Researchers can now investigate how transient c-Myc-Max inhibition impacts self-renewal capacity, differentiation, and senescence in hESCs or iPSCs, providing a window into developmental regulation and aging.
• Chromatin State Mapping: The rapid gain of H3K27me3 at the TERT promoter upon c-Myc-Max inhibition offers a robust assay for studying Polycomb group protein dynamics and epigenetic silencing mechanisms.
• Integration with Disease Models: While prior work such as '10058-F4: Small-Molecule c-Myc Inhibitor for Apoptosis Assays' delivers optimized workflows for cancer biology, our synthesis demonstrates how the same molecule drives fundamental advances in regenerative medicine and cell therapy research.

Best Practices: Handling and Experimental Considerations

10058-F4 is chemically defined as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one (MW 249.35, C₁₂H₁₁NOS₂). It is a solid compound, highly soluble (≥24.9 mg/mL) in DMSO and moderately soluble in ethanol (≥2.64 mg/mL), but insoluble in water (product_spec). For optimal reproducibility:

• Prepare stock solutions in DMSO at concentrations above 12.5 mg/mL; warming to 37°C or brief sonication enhances solubility.
• Aliquot and store at –20°C for several months; extended storage of solutions is discouraged due to potential degradation.
• For in vivo applications, ensure accurate dosing (20–30 mg/kg, i.v.) and monitor tumor response as efficacy may vary by xenograft model (source: product_spec).

Why this cross-domain matters, maturity, and limitations

The leap from oncology to stem cell and epigenetics research with 10058-F4 is grounded in direct evidence that c-Myc-Max dimerization regulates telomerase expression via chromatin modification in human pluripotent stem cells (reference paper). This cross-domain application is mature enough for advanced cell culture and chromatin immunoprecipitation experiments, but translation to in vivo models of telomere biology disorders will require further validation.

Conclusion and Future Outlook

10058-F4, available from APExBIO, is more than a c-Myc-Max dimerization inhibitor for apoptosis research. Its validated capacity to modulate telomerase transcription via epigenetic reprogramming in stem cells marks a paradigm shift, enabling researchers to probe fundamental mechanisms of aging, regeneration, and genomic stability. As the field moves toward precision interventions in telomere biology, 10058-F4 stands out as both a research staple and a catalyst for methodological innovation (reference paper).

For further details on advanced experimental design and troubleshooting, readers are encouraged to consult recent workflow-focused guides—our analysis builds a complementary bridge by highlighting new domains of application and mechanistic depth.